LT3482767T - Didinamos dozės fermentų pakaitinė terapija, skirta rūgštinės sfingomielinazės nepakankamumui gydyti - Google Patents

Didinamos dozės fermentų pakaitinė terapija, skirta rūgštinės sfingomielinazės nepakankamumui gydyti

Info

Publication number
LT3482767T
LT3482767T LTEP18199358.5T LT18199358T LT3482767T LT 3482767 T LT3482767 T LT 3482767T LT 18199358 T LT18199358 T LT 18199358T LT 3482767 T LT3482767 T LT 3482767T
Authority
LT
Lithuania
Prior art keywords
replacement therapy
dose escalation
enzyme replacement
acid sphingomyelinase
treating acid
Prior art date
Application number
LTEP18199358.5T
Other languages
English (en)
Inventor
Edward H. Schuchman
Robert J. Desnick
Gerald F. Cox
Laura P. Andrews
James M. Murray
Original Assignee
Icahn School Of Medicine At Mount Sinai
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3482767(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icahn School Of Medicine At Mount Sinai, Genzyme Corporation filed Critical Icahn School Of Medicine At Mount Sinai
Publication of LT3482767T publication Critical patent/LT3482767T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dermatology (AREA)
LTEP18199358.5T 2009-08-28 2010-08-28 Didinamos dozės fermentų pakaitinė terapija, skirta rūgštinės sfingomielinazės nepakankamumui gydyti LT3482767T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28

Publications (1)

Publication Number Publication Date
LT3482767T true LT3482767T (lt) 2022-01-10

Family

ID=43625265

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP18199358.5T LT3482767T (lt) 2009-08-28 2010-08-28 Didinamos dozės fermentų pakaitinė terapija, skirta rūgštinės sfingomielinazės nepakankamumui gydyti
LTEP10812683.0T LT2470199T (lt) 2009-08-28 2010-08-28 Pakaitinė fermento terapija su dozės didinimu, skirta rūgštinės sfingomielinazės nepakankamumo gydymui

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP10812683.0T LT2470199T (lt) 2009-08-28 2010-08-28 Pakaitinė fermento terapija su dozės didinimu, skirta rūgštinės sfingomielinazės nepakankamumo gydymui

Country Status (26)

Country Link
US (9) US8349319B2 (lt)
EP (3) EP3998078A1 (lt)
JP (7) JP5955219B2 (lt)
KR (5) KR102608551B1 (lt)
CN (3) CN102596232A (lt)
AU (5) AU2010286550B2 (lt)
BR (1) BR112012004377A2 (lt)
CA (1) CA2773133A1 (lt)
CL (1) CL2012000495A1 (lt)
CY (1) CY1122128T1 (lt)
DK (2) DK2470199T3 (lt)
ES (2) ES2738859T3 (lt)
FR (1) FR22C1062I2 (lt)
HR (2) HRP20211992T1 (lt)
HU (3) HUE046598T2 (lt)
IL (3) IL300625A (lt)
LT (2) LT3482767T (lt)
MX (1) MX356873B (lt)
NL (1) NL301211I2 (lt)
PL (2) PL3482767T3 (lt)
PT (2) PT2470199T (lt)
RU (3) RU2569744C2 (lt)
SI (2) SI2470199T1 (lt)
TR (1) TR201911293T4 (lt)
WO (1) WO2011025996A2 (lt)
ZA (2) ZA201201435B (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
ES2635726T3 (es) 2007-06-06 2017-10-04 Genzyme Corporation Terapia génica para enfermedades de almacenamiento lisosómico
RU2569744C2 (ru) * 2009-08-28 2015-11-27 Маунт Синай Скул Оф Медсин Ферментная заместительная терапия с увеличением дозы для лечения недостаточности кислой сфингомиелиназы
US8882701B2 (en) * 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
US20120034638A1 (en) 2010-05-21 2012-02-09 Michael Ahrens Electrochemical assay for the detection of enzymatically active PSA
JP6117708B2 (ja) 2011-03-18 2017-04-19 ジェンザイム・コーポレーション グルコシルセラミド合成酵素阻害剤
EP2753346B1 (en) 2011-09-07 2020-04-22 Mount Sinai School Of Medicine Ceramidase and cell differentiation
DK2780716T3 (da) * 2011-11-15 2019-10-14 Centogene Ag Fremgangsmåde til diagnose af Niemann-Pick sygdom
CA2874146C (en) 2012-06-01 2023-03-21 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
HUE046113T2 (hu) * 2013-03-14 2020-02-28 Icahn School Med Mount Sinai Terápiás sav ceramidáz készítmények és azok elõállítási és felhasználási eljárásai
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
ES2731920T3 (es) * 2013-05-14 2019-11-19 Centogene Ag Método para el diagnóstico de la enfermedad de Niemann-Pick
AU2014274670B2 (en) * 2013-06-07 2017-11-09 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
KR20200044064A (ko) 2017-08-24 2020-04-28 사노피 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
UY38238A (es) 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
BR112023000798A2 (pt) 2020-07-24 2023-02-07 Genzyme Corp Composições farmacêuticas compreendendo venglustat

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
ES2326705T3 (es) 1995-09-14 2009-10-16 Virginia Tech Intellectual Properties, Inc. Produccion de enzimas lisosomicas en sistemas de expresion basados en plantas.
JP2820106B2 (ja) 1996-02-29 1998-11-05 日本電気株式会社 トラヒックシェーパ装置
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
CN100410268C (zh) 1998-12-23 2008-08-13 博伊斯汤普生植物研究所 免疫原性的乙型肝炎表面抗原在转基因植物中的表达
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6770799B2 (en) 2000-03-17 2004-08-03 Thompson Boyce Plant Res Expression of recombinant human acetylcholinesterase in transgenic plants
AU2001269923A1 (en) * 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
WO2002018539A2 (en) 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ES2300439T3 (es) 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
US7527956B2 (en) * 2003-06-12 2009-05-05 Genzyme Corporation Modified human acid sphingomyelinase having increased activity, and methods for making the same
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
AU2004293115A1 (en) 2003-11-25 2005-06-09 Mount Sinai School Of Medicine Of New York University Chaperone-based therapy for Niemann-Pick disease
US8119406B2 (en) 2004-10-13 2012-02-21 Protalix Ltd. System and method for production of antibodies in plant cell culture
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
EP1960534A4 (en) 2005-12-15 2009-03-25 Univ New York State Res Found ENZYMATIC METHODS FOR MEASURING THE SPHINGOMYLELIN AND PHOSPHATIDYLCHOLIN SHARE IN PLASMA AND TISSUE
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
WO2007091250A2 (en) 2006-02-06 2007-08-16 The Medical Research And Infrastructure Fund Of The Tel-Aviv Sourasky Medical Center Enzyme replacement therapy for treating lysosomal storage diseases
EP1988823B1 (en) * 2006-02-09 2018-08-15 Genzyme Corporation Slow intraventricular delivery
BRPI0707733B1 (pt) 2006-02-13 2019-12-31 Fraunhofer Usa Inc antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
JP5302189B2 (ja) 2007-04-27 2013-10-02 長瀬産業株式会社 スフィンゴミエリナーゼ
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
EP3608330B1 (en) 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
RU2569744C2 (ru) * 2009-08-28 2015-11-27 Маунт Синай Скул Оф Медсин Ферментная заместительная терапия с увеличением дозы для лечения недостаточности кислой сфингомиелиназы
CN103764824B (zh) * 2011-06-20 2018-04-24 西奈山医学院 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法

Also Published As

Publication number Publication date
ES2738859T3 (es) 2020-01-27
AU2010286550A1 (en) 2012-03-15
SI2470199T1 (sl) 2019-11-29
WO2011025996A3 (en) 2012-03-15
FR22C1062I2 (fr) 2023-12-29
FR22C1062I1 (fr) 2023-02-03
US20220305091A1 (en) 2022-09-29
CL2012000495A1 (es) 2014-02-07
BR112012004377A2 (pt) 2017-12-12
JP6251307B2 (ja) 2017-12-20
PL2470199T3 (pl) 2019-11-29
US20130078230A1 (en) 2013-03-28
AU2024201085A1 (en) 2024-03-07
US20130078231A1 (en) 2013-03-28
DK3482767T3 (da) 2021-12-20
KR102608546B1 (ko) 2023-12-04
AU2018204156B2 (en) 2020-07-16
JP2020090513A (ja) 2020-06-11
PT2470199T (pt) 2019-08-07
AU2020256322A1 (en) 2020-11-12
CN105999238A (zh) 2016-10-12
CA2773133A1 (en) 2011-03-03
US9655954B2 (en) 2017-05-23
KR102608551B1 (ko) 2023-12-04
HUS2200050I1 (hu) 2022-12-28
EP2470199B1 (en) 2019-05-22
EP3482767A1 (en) 2019-05-15
JP2024026214A (ja) 2024-02-28
WO2011025996A9 (en) 2011-08-25
TR201911293T4 (tr) 2019-08-21
JP5955219B2 (ja) 2016-07-20
US20160120957A1 (en) 2016-05-05
AU2020256322B2 (en) 2024-02-29
AU2018204156A1 (en) 2018-06-28
JP2016153408A (ja) 2016-08-25
ZA201201435B (en) 2020-05-27
JP2022003065A (ja) 2022-01-11
HRP20211992T1 (hr) 2022-04-01
IL266915B2 (en) 2023-07-01
CY1122128T1 (el) 2020-11-25
SI3482767T1 (sl) 2022-03-31
JP7395693B2 (ja) 2023-12-11
CN106047835A (zh) 2016-10-26
KR20120081077A (ko) 2012-07-18
IL266915B1 (en) 2023-03-01
DK2470199T3 (da) 2019-08-05
RU2731616C2 (ru) 2020-09-07
US8658162B2 (en) 2014-02-25
JP2013502933A (ja) 2013-01-31
US9114139B2 (en) 2015-08-25
PL3482767T3 (pl) 2022-02-14
KR102094253B1 (ko) 2020-03-31
RU2569744C2 (ru) 2015-11-27
RU2015145255A3 (lt) 2019-08-12
IL218324A0 (en) 2012-04-30
KR20230164773A (ko) 2023-12-04
JP6952810B2 (ja) 2021-10-20
JP2023012499A (ja) 2023-01-25
NL301211I2 (nl) 2023-02-02
HRP20191385T1 (hr) 2019-11-01
HUE057440T2 (hu) 2022-05-28
MX356873B (es) 2018-06-18
EP2470199A4 (en) 2013-03-27
NL301211I1 (nl) 2022-12-28
US20190151419A1 (en) 2019-05-23
RU2020128994A (ru) 2022-03-02
CN102596232A (zh) 2012-07-18
AU2010286550B2 (en) 2016-05-19
EP3998078A1 (en) 2022-05-18
WO2011025996A2 (en) 2011-03-03
US20210077593A1 (en) 2021-03-18
KR20220104271A (ko) 2022-07-26
RU2015145255A (ru) 2019-01-11
AU2016216625B2 (en) 2018-07-05
US20140335070A1 (en) 2014-11-13
US10188705B2 (en) 2019-01-29
US20110052559A1 (en) 2011-03-03
MX2012002449A (es) 2012-03-14
ES2902229T3 (es) 2022-03-25
HUE046598T2 (hu) 2020-03-30
ZA201601362B (en) 2017-05-31
KR20200034828A (ko) 2020-03-31
IL266915A (en) 2019-07-31
EP3482767B1 (en) 2021-10-06
EP2470199A2 (en) 2012-07-04
US8709408B2 (en) 2014-04-29
PT3482767T (pt) 2021-12-29
AU2016216625A1 (en) 2016-09-15
IL300625A (en) 2023-04-01
US20180055916A1 (en) 2018-03-01
RU2012111823A (ru) 2013-10-10
IL218324B (en) 2019-05-30
KR20210107153A (ko) 2021-08-31
JP7167281B2 (ja) 2022-11-08
US8349319B2 (en) 2013-01-08
LT2470199T (lt) 2019-10-10
JP2018076322A (ja) 2018-05-17

Similar Documents

Publication Publication Date Title
HUS2200050I1 (hu) Dóziseszkalációs enzim helyettesítõ terápia savas szfingomielináz elégtelenség kezelésére
EP2308493A4 (en) ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
IL253293B (en) Desferrioxamine complexes of metals for the treatment of diseases related to the immune system
EP2166093A4 (en) PHARMACEUTICAL COMPOSITION FOR ENZYMATIC REPLACEMENT THERAPY
IL245283A0 (en) Use of lysosomal acid lipase to treat lysosomal acid lipase deficiency in patients
IL275350B (en) Treatment of neoplastic diseases
HK1163524A1 (zh) 胰腺腫瘤治療
PL2473172T3 (pl) Kompozycje bisfosfonianowe i sposoby do leczenia niewydolności serca
EP2675472A4 (en) METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
EP2397157A4 (en) PROMOTER OF DIFFERENTIATION OF CEREBRAL TUMOR STEM CELLS AND THERAPEUTIC AGENT FOR USE IN CEREBRAL TUMORS
ZA201301279B (en) Preventive or therapeutic agent for fibrosis
ZA201009063B (en) Diaryl ureas for treating heart failure
IL216491A0 (en) Combination therapy for the treatment of multiple myeloma
EP2486929A4 (en) ANTI-TUMOR THERAPEUTIC AGENT
ZA201201894B (en) Pharmaceutical combination for treating tumor
GB0909239D0 (en) Targeted gene therapy
IL218160A0 (en) Desferrioxamine-metal complexes for the treatment of immune-related disorders